All News
@DrDDRheum @DrErickZamora1 @hoffmann_vold If you have a normal HRCT and echo does a PFT at same time point add anything? Issues with getting PFTs in covid times #ACR20 @rheumnow @sclerodermaUM
Richard Conway RichardPAConway ( View Tweet)
This single slide tries to summarise all major phase3 clinical trials in Psoriatic Arthritis đź’Ş
Take your time. The top half looks at joint efficacy. The bottom half for skin efficacy.
#ACR20 https://t.co/FXhJunXNKt
Dr Irwin Lim _connectedcare ( View Tweet)
Reducing Immunogenicity of Pegloticase (RECIPE) w/ concomitant use of MMF in pts w/ refractory gout is a phase II double blind RCT that shows sustained serum urate lowering effect in addition to decrease in monthly rate of flares. #ACRbest #Abst0952 @RheumNow Practice changing? https://t.co/Z7GwCXZftE
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers https://t.co/fRB2zuKl5J #gout #uricosuric a novel uricosuric agent
Peter Nash drpnash ( View Tweet)
Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect https://t.co/T9IqF7E00Z #OA #DMOAD a potential DMOAD in mice
Peter Nash drpnash ( View Tweet)
Next up! #Autoinflammatory diseases: mechanisms and management. First: CRMO & SAPHO with Dr. Polly Ferguson
Highlights:
đź“ŤThe *many* names of CRMO/CNO
đź“ŤClinical features
đź“ŤRx options (NSAIDs, bisphosphonates, TNFi)
đź“ŤRole of innate immunity in etiology
#ACRambassador https://t.co/qP3IySJKGC
Danny Soulsby dsoulsMD ( View Tweet)
Genotype analysis define new illnesses such as VEXAS.
”Somatic mutation may account for a significant fraction of adult-onset inflammatory disease” says Dr. Dan Castner.
Science enthusiasm at 3S038. Autoinflammatory Diseases.
@petercgrayson #ACR20 <TK https://t.co/gyTxF8NWtO
ARD & RMD Open ARD_BMJ ( View Tweet)
Based on RECIPE, how many of you will use MMF concomitantly with start of pegloticase in treating refractory gout patients? #ACR20 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
@drdavidliew @VasculitisUMCG @RheumNow Dear David, thanks for your interest in our abstract #ACR20. This is based on some intriguing findings found in our previous observational study https://t.co/HKm53j2xou Still a work in progress but the potential adjunctive anti-inflammatory effect of ARBs seems attractive.
Marco A Alba, MD, PhD MA_ALBA_vascul ( View Tweet)
Dr. Anthony Fauci at #ACR20 -
“We are cautiously optimistic that we will have a safe and effective vaccine at the end of this calendar year and may be able to deploy in individuals with a high risk beginning in early 2021.”
@RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Etanercept monotherapy significantly more effective than Methotrexate monotherapy in maintaining remission in RA patients on combination therapy. Data from the SEAM-RA study @RheumNow #ACR20 Abstr#0939 #ACRbest
Dr. Antoni Chan synovialjoints ( View Tweet)
Neighbourhood characteristics & socioeconomic factors important not only for contracting #COVID19 but also severe infection in #SLE. Results useful for developing strategies to address socioeconomic stressors in this population.
Abs#0984 #ACR20 @RheumNow
https://t.co/u4YDcfEcSQ
Mrinalini Dey DrMiniDey ( View Tweet)
Dan Kastner quoting Clement Clark Moore "visions of sugar plums dancing in our heads" looking forward to the new era of molecular taxonomy of rheumatic disease heralded by the discovery of VEXAS #ACR20 @rheumnow
Richard Conway RichardPAConway ( View Tweet)
Test your knowledge of day 2 of the #ACR20 meeting. Take our daily ACR IQ quiz and see where you stack up on the leaderboard.
https://t.co/8O5vN9Uto5 https://t.co/tx32siM7a3
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Fascinating and engaging talk by Dr. Kastner on the discovery of VEXAS using a genotype-first strategy. Definitely one to go back and watch if you missed it! #ACR20 https://t.co/D090V7HiG2
E. Sloan esloanmd ( View Tweet)
Dan Kastner giving an absolute tour de force of the discovery of VEXAS in autoinflammatory diseases: mechanisms and management session now. If you aren't listening, watch it back! #ACR20 @rheumnow https://t.co/zell5e2Brt
Richard Conway RichardPAConway ( View Tweet)
Older patients with polypharmacy are at ⬆ risk for drug-drug reactions and adverse effects. @RheumNow #ACR20 https://t.co/uKsYO9B8PZ
sheila RHEUMarampa ( View Tweet)
Management of elderly patients with rheumatic diseases. Dr Rajasimhan. #ACR20 @RheumNow. Also we are near of first therapeutic recommendations of elderly #sjogren syndrome @ramos_casals @p_brito_zeron https://t.co/yjGrSTWV1K
Sole RetamozoSole ( View Tweet)
Ultrasound to assess synovial-entheses junction correlated with clinical findings Abs#0311
Do you use MSK US in your clinic? @RheumNow #ACR20
Robert B Chao, MD doctorRBC ( View Tweet)